Each additional month of survival matters profoundly for these patients.
Em um campo onde o progresso costuma ser medido em semanas, a Anvisa abriu em abril de 2025 uma nova possibilidade para pacientes brasileiros com câncer de pâncreas metastático — uma doença que, na maioria das vezes, só se revela quando já não há muito espaço para recuar. A aprovação do irinotecan lipossomal peguilado representa não apenas um avanço farmacológico, mas o reconhecimento de que pacientes que esgotaram a primeira linha de tratamento merecem uma alternativa com evidências sólidas por trás. É um passo modesto em números absolutos, mas imenso em dignidade clínica.
- O câncer de pâncreas é diagnosticado em estágio avançado em 80% dos casos, deixando pacientes com opções terapêuticas drasticamente reduzidas desde o início.
- Até agora, quem progredia após a quimioterapia inicial com gencitabina enfrentava um vazio clínico real — sem alternativa eficaz comprovada por ensaios rigorosos.
- O estudo NAPOLI-1 demonstrou que o novo medicamento reduz o risco de morte em 33% e dobra a taxa de controle da doença em relação ao regime padrão.
- A tecnologia de encapsulamento lipídico permite que o fármaco permaneça ativo por até 168 horas no organismo, contra apenas 24 horas da formulação convencional, ampliando a eficácia com doses menores.
- A disponibilidade efetiva no Brasil depende ainda da regulação de preços pela CMED, com previsão de chegada ao mercado no segundo semestre de 2025.
No dia 28 de abril, a Anvisa aprovou o irinotecan lipossomal peguilado, tornando o Brasil o mais recente entre 47 países a oferecer essa opção a pacientes com adenocarcinoma pancreático metastático que não responderam ao tratamento inicial. A chegada do medicamento ao mercado ainda depende de negociações de preço, mas a expectativa é que esteja disponível ainda em 2025.
O adenocarcinoma pancreático responde por cerca de 90% dos casos de câncer de pâncreas no país e figura entre as causas mais letais de morte por câncer. Sua crueldade está, em parte, na invisibilidade: sintomas vagos como dor abdominal e perda de peso retardam o diagnóstico, e quatro em cada cinco pacientes chegam ao médico com a doença já disseminada. Para quem progredia após a gencitabina, não havia, até agora, nenhuma alternativa terapêutica respaldada por evidências robustas.
O ensaio clínico de fase 3 NAPOLI-1 mudou esse cenário. Pacientes tratados com a nova combinação sobreviveram em mediana 6,1 meses, contra 4,2 meses no grupo controle — uma redução de 33% no risco de morte. O tempo livre de progressão da doença também dobrou, e 52% dos pacientes alcançaram controle da doença, comparado a 24% com o regime padrão. Um dado especialmente significativo: um quarto dos pacientes ainda estava vivo após um ano, um marco raro nessa enfermidade.
A eficácia do medicamento está ligada à sua formulação: o princípio ativo é encapsulado em uma camada lipídica que o direciona aos tumores com maior precisão e o mantém ativo por até 168 horas — sete vezes mais do que a versão convencional. Isso permite doses menores com efeito equivalente, potencialmente reduzindo efeitos colaterais.
Para o oncologista Thiago Felismino, do A.C. Camargo Cancer Center, a aprovação representa uma virada para pacientes que antes chegavam ao fim da primeira linha sem para onde ir. Em uma doença onde cada mês adicional de vida carrega peso imenso, ter uma opção com dados concretos não é pouco — é, para muitos, a diferença entre um corredor sem saída e uma porta que finalmente se abre.
Brazil's health regulator approved a new chemotherapy drug on April 28th, marking the first time patients with advanced pancreatic cancer have access to a proven second-line treatment after their initial therapy fails. The medication, pegylated liposomal irinotecan, will be administered intravenously alongside two companion drugs and is expected to reach patients by the second half of this year, pending price negotiations.
The approval addresses a stark clinical reality: pancreatic adenocarcinoma, the most common form of pancreatic cancer, accounts for roughly 90 percent of all cases in the country and ranks 14th among cancer types by frequency, responsible for about 5 percent of cancer deaths. The disease is brutally aggressive. Approximately 80 percent of patients receive their diagnosis only after the cancer has already spread to distant sites, when treatment options narrow considerably. Even when caught early, about half of all patients experience recurrence. Until now, those whose tumors progressed after initial gemcitabine therapy had no effective alternative backed by rigorous clinical evidence.
The approval rests on data from the NAPOLI-1 phase 3 trial, which demonstrated substantial benefits. Patients receiving the new drug combined with two other chemotherapy agents survived a median of 6.1 months compared to 4.2 months in the control group—a 33 percent reduction in death risk. They also remained free of disease progression for 3.1 months versus 1.5 months in controls. The combination achieved disease control in 52 percent of patients, nearly double the 24 percent rate seen with the standard regimen alone. Perhaps most strikingly, one quarter of patients treated with the combination were still alive one year later, a milestone that carries profound weight in a disease historically defined by rapid deterioration.
The drug works through an encapsulation technology that wraps the active medication in a lipid shell, allowing it to reach tumors more effectively and in higher concentrations. The active agent remains in the body for up to 168 hours, compared to just 24 hours for the conventional version of the same drug, which means 90 percent of the standard formulation is already eliminated within a day. This extended exposure allows doctors to use smaller doses while achieving the same therapeutic effect, potentially reducing side effects while maintaining efficacy.
Thiago Felismino, a clinical oncologist at A.C. Camargo Cancer Center, emphasized the significance of the approval. He noted that pancreatic cancer presents with vague early symptoms—abdominal pain, weight loss, sometimes back pain—that make diagnosis difficult. The new option represents a robust alternative for patients who have exhausted their first-line options and faced a therapeutic dead end. Each additional month of survival matters profoundly for these patients, he stressed, and the trial data demonstrates clear progress in an area where alternatives were virtually nonexistent.
The medication is already approved and available in 47 countries, including the United States and across the European Union. In Brazil, the next step involves price regulation through the government's pharmaceutical pricing board. Once that process concludes, physicians can prescribe the drug to eligible patients meeting the approved indication. For a population facing one of oncology's most formidable challenges, this approval opens a door that was previously locked.
Notable Quotes
With this approval, we now have a robust alternative for patients who previously had no effective treatment options after gemcitabine failure in metastatic disease—an advance aimed at improving survival and quality of life.— Thiago Felismino, clinical oncologist at A.C. Camargo Cancer Center
Each additional month of survival is fundamental for patients, and the NAPOLI-1 data clearly shows we are advancing in an area where alternatives were extremely limited.— Thiago Felismino
The Hearth Conversation Another angle on the story
Why does this approval matter so much if the survival gain is measured in months?
Because in pancreatic cancer, months are not small. Most patients with metastatic disease die within a year. Gaining 1.9 additional months of median survival, and having a quarter of patients reach one year—that's not marginal. That's the difference between hope and none.
The article mentions the drug was already approved in the US and Europe. Why did Brazil take so long?
Different regulatory timelines. Anvisa moves at its own pace. But the important thing is it's here now, and the approval was based on the same rigorous trial data that convinced the FDA and EMA.
What about cost? Will patients actually be able to afford this?
That's the open question. The drug has been approved, but pricing hasn't been set yet. In Brazil, that's a separate negotiation with the government. Some patients will access it through the public system if it's approved for coverage. Others through private insurance. Some won't be able to afford it at all.
The article says 80 percent of patients are diagnosed late. Can't doctors catch it earlier?
The symptoms are too vague. Abdominal pain, weight loss—those could be a dozen things. By the time someone suspects pancreatic cancer, it's usually advanced. There's no good early screening test like there is for some other cancers.
So this drug doesn't cure anyone?
No. It extends life and improves quality of life for some patients. In a disease this aggressive, that's what we have. The goal shifts from cure to buying time, to living better in the time you have.